Life Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109-2216, USA.
J Med Chem. 2010 Feb 25;53(4):1867-70. doi: 10.1021/jm9017515.
G protein-coupled receptor kinase 2 (GRK2) is a pharmaceutical target for the treatment of cardiovascular diseases such as congestive heart failure, myocardial infarction, and hypertension. To better understand how nanomolar inhibition and selectivity for GRK2 might be achieved, we have determined crystal structures of human GRK2 in complex with Gbetagamma in the presence and absence of the AGC kinase inhibitor balanol. The selectivity of balanol among human GRKs is assessed.
G 蛋白偶联受体激酶 2(GRK2)是治疗充血性心力衰竭、心肌梗死和高血压等心血管疾病的药物靶点。为了更好地理解如何实现对 GRK2 的纳摩尔抑制和选择性,我们已经确定了人源 GRK2 与 Gbetagamma 复合物的晶体结构,其中存在和不存在 AGC 激酶抑制剂巴兰诺。评估了巴兰诺在人源 GRK 中的选择性。